Poolbeg Pharma is to commence a human challenge trial for its lead molecule POLB 001, a small molecule immunomodulator intended for the treatment of severe influenza, marking delivery against an important commitment made in its IPO a year ago. The company has received ethics and competent authority
20 Jul 2022
Poolbeg ready to commence POLB 001 clinical study
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Poolbeg ready to commence POLB 001 clinical study
Poolbeg Pharma PLC (POLB:LON) | 10.6 0 2.4% | Mkt Cap: 53.0m
- Published:
20 Jul 2022 -
Author:
Robin Davison -
Pages:
3
Poolbeg Pharma is to commence a human challenge trial for its lead molecule POLB 001, a small molecule immunomodulator intended for the treatment of severe influenza, marking delivery against an important commitment made in its IPO a year ago. The company has received ethics and competent authority